BCLI
Brainstorm Cell Therapeutics Inc.
Price Chart
Latest Quote
$0.83
+0.07 (+9.21%)
Current Price
| Previous Close | $0.76 |
| Open | $0.77 |
| Day High | $0.83 |
| Day Low | $0.77 |
| Volume | 1,459 |
Stock Information
| Shares Outstanding | 11.03M |
| Total Debt | $1.18M |
| Cash Equivalents | $29K |
| Net Income | $-10.31M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.28M |
| EPS (TTM) | $-0.85 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.42M |
| Income | $-10.31M |
| Book/sh | $-0.91 |
| Cash/sh | $0.00 |
| Employees | 20 |
Financial Ratios
| Quick Ratio | 0.01 |
| Current Ratio | 0.03 |
Returns & Margins
| ROA | -435.92% |
Ownership
| Insider Ownership | 10.27% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.87 |
| P/B | -0.83 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.74 |
| SMA50 | $0.76 |
| SMA200 | $0.69 |
| RSI | 56.60 |
| ATR | 0.0993 |
| Shares Float | 9.92M |
| Short Float | 6.46% |
| Short Ratio | 1.27 |
| Volatility | 0.28 |
| Rel Volume | 0.44 |
Performance History
| Week | +0.00% |
| Month | +8.70% |
| Quarter | +0.00% |
| 6 Months | +33.93% |
| YTD | +22.95% |
| Year | -39.52% |
| 3 Years | -98.30% |
| 5 Years | -98.73% |
| 10 Years | -97.91% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $0.75 | 5,800 |
| 2026-06-11 | $0.77 | 4,400 |
| 2026-06-10 | $0.83 | 33,000 |
| 2026-06-09 | $0.76 | 7,800 |
| 2026-06-08 | $0.80 | 11,600 |
| 2026-06-05 | $0.75 | 28,100 |
| 2026-06-04 | $0.79 | 9,100 |
| 2026-06-03 | $0.77 | 7,300 |
| 2026-06-02 | $0.79 | 4,900 |
| 2026-06-01 | $0.75 | 43,000 |
| 2026-05-29 | $0.75 | 4,500 |
| 2026-05-28 | $0.72 | 13,300 |
| 2026-05-27 | $0.69 | 5,700 |
| 2026-05-26 | $0.63 | 26,500 |
| 2026-05-22 | $0.68 | 1,800 |
| 2026-05-21 | $0.71 | 27,300 |
| 2026-05-20 | $0.72 | 1,400 |
| 2026-05-19 | $0.71 | 6,400 |
| 2026-05-18 | $0.69 | 15,800 |
| 2026-05-15 | $0.69 | 7,800 |
| 2026-05-14 | $0.69 | 6,300 |
| 2026-05-13 | $0.69 | 1,200 |
About Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on BCLI.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $11,693,000 | $21,439,000 | $24,822,000 | $24,539,000 |
| Other Income Expense | $147,000 | $4,694,000 | - | - |
| Net Non Operating Interest Income Expense | $-77,000 | $-447,000 | $545,000 | $82,000 |
| Total Other Finance Cost | $77,000 | $447,000 | $-545,000 | $-82,000 |
| Operating Expense | $11,693,000 | $21,439,000 | $24,822,000 | $24,539,000 |
| General And Administrative Expense | $7,042,000 | $10,693,000 | $10,866,000 | $9,304,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,623,000 | $-17,192,000 | $-24,277,000 | $-24,457,000 |
| Net Interest Income | $-77,000 | $-447,000 | $545,000 | $82,000 |
| Normalized Income | $-11,770,000 | $-21,886,000 | $-24,277,000 | $-24,457,000 |
| Net Income From Continuing And Discontinued Operation | $-11,623,000 | $-17,192,000 | $-24,277,000 | $-24,457,000 |
| Total Operating Income As Reported | $-11,693,000 | $-21,439,000 | $-24,822,000 | $-24,539,000 |
| Net Income Common Stockholders | $-11,623,000 | $-17,192,000 | $-24,277,000 | $-24,457,000 |
| Net Income | $-11,623,000 | $-17,192,000 | $-24,277,000 | $-24,457,000 |
| Net Income Including Noncontrolling Interests | $-11,623,000 | $-17,192,000 | $-24,277,000 | $-24,457,000 |
| Net Income Continuous Operations | $-11,623,000 | $-17,192,000 | $-24,277,000 | $-24,457,000 |
| Pretax Income | $-11,623,000 | $-17,192,000 | $-24,277,000 | $-24,457,000 |
| Operating Income | $-11,693,000 | $-21,439,000 | $-24,822,000 | $-24,539,000 |
| Interest Income | - | - | $545,000 | $82,000 |
| Interest Income Non Operating | - | - | $545,000 | $82,000 |
| Per Share | ||||
| Diluted EPS | $-2.31 | $-6.00 | $-9.90 | $-10.20 |
| Basic EPS | $-2.31 | $-6.00 | $-9.90 | $-10.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,600,000 | $-25,868,000 | $-24,537,000 | $-24,279,000 |
| Total Unusual Items | $147,000 | $4,694,000 | - | - |
| Total Unusual Items Excluding Goodwill | $147,000 | $4,694,000 | - | - |
| Reconciled Depreciation | $240,000 | $265,000 | $285,000 | $260,000 |
| EBITDA (Bullshit earnings) | $-11,453,000 | $-21,174,000 | $-24,537,000 | $-24,279,000 |
| EBIT | $-11,693,000 | $-21,439,000 | $-24,822,000 | $-24,539,000 |
| Diluted Average Shares | $5,021,798 | $2,871,729 | $2,433,937 | $2,412,116 |
| Basic Average Shares | $5,021,798 | $2,871,729 | $2,433,937 | $2,412,116 |
| Diluted NI Availto Com Stockholders | $-11,623,000 | $-17,192,000 | $-24,277,000 | $-24,457,000 |
| Gain On Sale Of Security | $147,000 | $4,694,000 | - | - |
| Research And Development | $4,651,000 | $10,746,000 | $13,956,000 | $15,235,000 |
| Selling General And Administration | $7,042,000 | $10,693,000 | $10,866,000 | $9,304,000 |
| Other Gand A | $7,042,000 | $10,693,000 | $10,866,000 | $9,304,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-7,764,000 | $-4,858,000 | $-3,015,000 | $19,342,000 |
| Total Assets | $1,832,000 | $4,208,000 | $8,451,000 | $29,277,000 |
| Total Non Current Assets | $1,447,000 | $2,309,000 | $5,345,000 | $5,997,000 |
| Other Non Current Assets | $206,000 | $207,000 | $23,000 | $27,000 |
| Current Assets | $385,000 | $1,899,000 | $3,106,000 | $23,280,000 |
| Other Current Assets | $135,000 | $548,000 | $32,000 | $1,100,000 |
| Receivables | $63,000 | $51,000 | $91,000 | $86,000 |
| Other Receivables | $63,000 | $51,000 | $91,000 | $86,000 |
| Cash Cash Equivalents And Short Term Investments | $187,000 | $1,300,000 | $2,983,000 | $22,094,000 |
| Cash And Cash Equivalents | $187,000 | $1,300,000 | $772,000 | $18,856,000 |
| Non Current Prepaid Assets | - | $22,000 | $23,000 | $27,000 |
| Prepaid Assets | - | - | - | $1,100,000 |
| Debt | ||||
| Total Debt | $720,000 | $1,275,000 | $4,093,000 | $5,079,000 |
| Long Term Debt And Capital Lease Obligation | $171,000 | $672,000 | $2,666,000 | $3,618,000 |
| Current Debt And Capital Lease Obligation | $549,000 | $603,000 | $1,427,000 | $1,461,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,596,000 | $9,066,000 | $11,466,000 | $9,935,000 |
| Total Non Current Liabilities Net Minority Interest | $618,000 | $1,266,000 | $2,666,000 | $3,618,000 |
| Derivative Product Liabilities | $447,000 | $594,000 | $0 | - |
| Current Liabilities | $8,978,000 | $7,800,000 | $8,800,000 | $6,317,000 |
| Payables And Accrued Expenses | $6,999,000 | $6,194,000 | $6,308,000 | $4,856,000 |
| Payables | $6,380,000 | $4,954,000 | $6,224,000 | $4,773,000 |
| Accounts Payable | $6,080,000 | $4,954,000 | $6,224,000 | $4,773,000 |
| Equity | ||||
| Common Stock Equity | $-7,764,000 | $-4,858,000 | $-3,015,000 | $19,342,000 |
| Total Equity Gross Minority Interest | $-7,764,000 | $-4,858,000 | $-3,015,000 | $19,342,000 |
| Stockholders Equity | $-7,764,000 | $-4,858,000 | $-3,015,000 | $19,342,000 |
| Retained Earnings | $-226,636,000 | $-215,013,000 | $-197,821,000 | $-173,544,000 |
| Other | ||||
| Treasury Shares Number | $1,667 | - | - | - |
| Ordinary Shares Number | $6,141,762 | $4,032,613 | $2,446,271 | $2,426,760 |
| Share Issued | $6,143,429 | $4,032,613 | $2,446,271 | $2,426,760 |
| Tangible Book Value | $-7,764,000 | $-4,858,000 | $-3,015,000 | $19,342,000 |
| Invested Capital | $-7,764,000 | $-4,858,000 | $-3,015,000 | $19,342,000 |
| Working Capital | $-8,593,000 | $-5,901,000 | $-5,694,000 | $16,963,000 |
| Capital Lease Obligations | $720,000 | $1,275,000 | $4,093,000 | $5,079,000 |
| Total Capitalization | $-7,764,000 | $-4,858,000 | $-3,015,000 | $19,342,000 |
| Treasury Stock | $116,000 | $116,000 | $116,000 | $116,000 |
| Additional Paid In Capital | $218,974,000 | $210,258,000 | $194,910,000 | $192,990,000 |
| Capital Stock | $14,000 | $13,000 | $12,000 | $12,000 |
| Common Stock | $14,000 | $13,000 | $12,000 | $12,000 |
| Long Term Capital Lease Obligation | $171,000 | $672,000 | $2,666,000 | $3,618,000 |
| Current Capital Lease Obligation | $549,000 | $603,000 | $1,427,000 | $1,461,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,430,000 | $1,003,000 | $1,065,000 | - |
| Current Accrued Expenses | $619,000 | $1,240,000 | $84,000 | $83,000 |
| Dueto Related Parties Current | $300,000 | $0 | - | - |
| Net PPE | $1,241,000 | $2,102,000 | $5,322,000 | $5,970,000 |
| Accumulated Depreciation | $-3,003,000 | $-2,763,000 | $-2,498,000 | $-2,213,000 |
| Gross PPE | $4,244,000 | $4,865,000 | $7,820,000 | $8,183,000 |
| Leases | $837,000 | $837,000 | $837,000 | $814,000 |
| Other Properties | $3,083,000 | $3,704,000 | $6,662,000 | $7,054,000 |
| Machinery Furniture Equipment | $324,000 | $324,000 | $321,000 | $315,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | $0 | $2,211,000 | $3,238,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,093,000 | $-20,476,000 | $-19,349,000 | $-26,595,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,093,000 | $-20,458,000 | $-19,320,000 | $-26,265,000 |
| Cash Flow From Continuing Operating Activities | $-9,093,000 | $-20,458,000 | $-19,320,000 | $-26,265,000 |
| Operating Gains Losses | $-147,000 | $-4,525,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $12,000 | $2,193,000 | $998,000 | $323,000 |
| Cash Flow From Continuing Investing Activities | $12,000 | $2,193,000 | $998,000 | $323,000 |
| Capital Expenditure | - | $-18,000 | $-29,000 | $-330,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $7,967,000 | $18,978,000 | $238,000 | $6,964,000 |
| Financing Cash Flow | $7,967,000 | $18,978,000 | $238,000 | $6,969,000 |
| Cash Flow From Continuing Financing Activities | $7,967,000 | $18,978,000 | $238,000 | $6,969,000 |
| Net Common Stock Issuance | $7,967,000 | $18,978,000 | $238,000 | $6,964,000 |
| Common Stock Issuance | $7,967,000 | $18,978,000 | $238,000 | $6,964,000 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Other | ||||
| End Cash Position | $371,000 | $1,485,000 | $772,000 | $18,856,000 |
| Beginning Cash Position | $1,485,000 | $772,000 | $18,856,000 | $37,829,000 |
| Changes In Cash | $-1,114,000 | $713,000 | $-18,084,000 | $-18,973,000 |
| Net Investment Purchase And Sale | $0 | $2,211,000 | $1,027,000 | $653,000 |
| Net PPE Purchase And Sale | $12,000 | $-18,000 | $-29,000 | $-330,000 |
| Sale Of PPE | $12,000 | - | - | - |
| Change In Working Capital | $1,687,000 | $-496,000 | $2,990,000 | $-3,434,000 |
| Change In Other Current Liabilities | $54,000 | $155,000 | $-594,000 | $-47,000 |
| Change In Payables And Accrued Expense | $1,232,000 | $-176,000 | $2,517,000 | $-3,722,000 |
| Change In Payable | $1,232,000 | $-176,000 | $2,517,000 | $-3,722,000 |
| Change In Account Payable | $1,126,000 | $-1,270,000 | $2,524,000 | $-1,717,000 |
| Change In Prepaid Assets | $401,000 | $-475,000 | - | - |
| Stock Based Compensation | $750,000 | $1,490,000 | $1,682,000 | $1,366,000 |
| Depreciation Amortization Depletion | $240,000 | $265,000 | $285,000 | $260,000 |
| Depreciation And Amortization | $240,000 | $265,000 | $285,000 | $260,000 |
| Depreciation | $240,000 | $265,000 | $285,000 | $260,000 |
| Gain Loss On Investment Securities | $-147,000 | $-4,525,000 | - | - |
| Net Income From Continuing Operations | $-11,623,000 | $-17,192,000 | $-24,277,000 | $-24,457,000 |
| Purchase Of PPE | - | $-18,000 | $-29,000 | $-330,000 |
| Change In Receivables | - | $-475,000 | $1,067,000 | $335,000 |
| Proceeds From Stock Option Exercised | - | - | $0 | $5,000 |
| Common Stock Payments | - | - | - | $0 |
Fetched: 2026-02-02